Literature DB >> 9291300

Challenge of BALB/c mice with respiratory syncytial virus does not enhance the Th2 pathway induced after immunization with a recombinant G fusion protein, BBG2NA, in aluminum hydroxide.

N Corvaïa1, P Tournier, T N Nguyen, J F Haeuw, U F Power, H Binz, C Andréoni.   

Abstract

The polypeptide of aa 130-230 of the G protein (G2Na) of respiratory syncytial virus (RSV) was fused to BB, the albumin-binding region of streptococcal G protein, producing BBG2Na, which induced protective immune responses in rodent models. Evaluation of the immune response in mice immunized with BBG2Na in the adjuvant alhydrogel revealed high amounts of interleukin (IL)-5 and some IL-4 in splenocytes restimulated in vitro. This is compatible with a Th2 response. The activation of the Th2 pathway in such mice was further supported by the detection of IL-5 and G2Na-specific IgE in vivo. Of interest, in contrast to immunization with formalin-inactivated RSV, immunization of mice with BBG2Na followed by intranasal RSV challenge did not lead to increased production of IL-5- or G2Na-specific IgE. However, IgG1- and IgG2a-specific antibodies were boosted. These results demonstrate that the Th2 pathway is not enhanced by RSV challenge in BBG2Na-immunized mice.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9291300     DOI: 10.1086/514075

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  13 in total

Review 1.  Respiratory syncytial virus (RSV) evades the human adaptive immune system by skewing the Th1/Th2 cytokine balance toward increased levels of Th2 cytokines and IgE, markers of allergy--a review.

Authors:  Yechiel Becker
Journal:  Virus Genes       Date:  2006-10       Impact factor: 2.332

2.  Differential histopathology and chemokine gene expression in lung tissues following respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV- or BBG2Na-immunized mice.

Authors:  U F Power; T Huss; V Michaud; H Plotnicky-Gilquin; J Y Bonnefoy; T N Nguyen
Journal:  J Virol       Date:  2001-12       Impact factor: 5.103

3.  Identification of multiple protective epitopes (protectopes) in the central conserved domain of a prototype human respiratory syncytial virus G protein.

Authors:  H Plotnicky-Gilquin; L Goetsch; T Huss; T Champion; A Beck; J F Haeuw; T N Nguyen; J Y Bonnefoy; N Corvaïa; U F Power
Journal:  J Virol       Date:  1999-07       Impact factor: 5.103

4.  CD4(+) T-cell-mediated antiviral protection of the upper respiratory tract in BALB/c mice following parenteral immunization with a recombinant respiratory syncytial virus G protein fragment.

Authors:  H Plotnicky-Gilquin; A Robert; L Chevalet; J F Haeuw; A Beck; J Y Bonnefoy; C Brandt; C A Siegrist; T N Nguyen; U F Power
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

5.  Gamma interferon-dependent protection of the mouse upper respiratory tract following parenteral immunization with a respiratory syncytial virus G protein fragment.

Authors:  Helene Plotnicky-Gilquin; Dominique Cyblat-Chanal; Jean-Pierre Aubry; Thierry Champion; Alain Beck; Thien Nguyen; Jean-Yves Bonnefoy; Nathalie Corvaïa
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

6.  Vaccination to induce antibodies blocking the CX3C-CX3CR1 interaction of respiratory syncytial virus G protein reduces pulmonary inflammation and virus replication in mice.

Authors:  Wenliang Zhang; Youngjoo Choi; Lia M Haynes; Jennifer L Harcourt; Larry J Anderson; Les P Jones; Ralph A Tripp
Journal:  J Virol       Date:  2009-10-28       Impact factor: 5.103

7.  Single intranasal immunization with recombinant adenovirus-based vaccine induces protective immunity against respiratory syncytial virus infection.

Authors:  Jae-Rang Yu; Sol Kim; Jee-Boong Lee; Jun Chang
Journal:  J Virol       Date:  2007-12-19       Impact factor: 5.103

8.  Immunogenicity and efficacy of recombinant RSV-F vaccine in a mouse model.

Authors:  Shree R Singh; Vida A Dennis; Christina L Carter; Shreekumar R Pillai; Ayanna Jefferson; Shivendra V Sahi; Eddie G Moore
Journal:  Vaccine       Date:  2007-06-26       Impact factor: 3.641

9.  Current research on respiratory viral infections: Fifth International Symposium.

Authors:  Michael G Ison; Sebastian L Johnston; Peter Openshaw; Brian Murphy; Frederick Hayden
Journal:  Antiviral Res       Date:  2004-06       Impact factor: 5.970

Review 10.  Respiratory syncytial virus vaccines.

Authors:  R A Dudas; R A Karron
Journal:  Clin Microbiol Rev       Date:  1998-07       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.